Literature DB >> 23076838

Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.

Selma F Mohammed1, Barry A Borlaug, Véronique L Roger, Sultan A Mirzoyev, Richard J Rodeheffer, Julio A Chirinos, Margaret M Redfield.   

Abstract

BACKGROUND: Patients with heart failure and preserved ejection fraction (HFpEF) display increased adiposity and multiple comorbidities, factors that in themselves may influence cardiovascular structure and function. This has sparked debate as to whether HFpEF represents a distinct disease or an amalgamation of comorbidities. We hypothesized that fundamental cardiovascular structural and functional alterations are characteristic of HFpEF, even after accounting for body size and comorbidities. METHODS AND
RESULTS: Comorbidity-adjusted cardiovascular structural and functional parameters scaled to independently generated and age-appropriate allometric powers were compared in community-based cohorts of HFpEF patients (n=386) and age/sex-matched healthy n=193 and hypertensive, n=386 controls. Within HFpEF patients, body size and concomitant comorbidity-adjusted cardiovascular structural and functional parameters and survival were compared in those with and without individual comorbidities. Among HFpEF patients, comorbidities (obesity, anemia, diabetes mellitus, and renal dysfunction) were each associated with unique clinical, structural, functional, and prognostic profiles. However, after accounting for age, sex, body size, and comorbidities, greater concentric hypertrophy, atrial enlargement and systolic, diastolic, and vascular dysfunction were consistently observed in HFpEF compared with age/sex-matched normotensive and hypertensive.
CONCLUSIONS: Comorbidities influence ventricular-vascular properties and outcomes in HFpEF, yet fundamental disease-specific changes in cardiovascular structure and function underlie this disorder. These data support the search for mechanistically targeted therapies in this disease.

Entities:  

Mesh:

Year:  2012        PMID: 23076838      PMCID: PMC3767407          DOI: 10.1161/CIRCHEARTFAILURE.112.968594

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  41 in total

Review 1.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease.

Authors:  Edward G Lakatta; Daniel Levy
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

2.  Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats.

Authors:  G Olivetti; F Quaini; C Lagrasta; R Ricci; G Tiberti; J M Capasso; P Anversa
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

3.  Obesity paradox as a component of reverse epidemiology in heart failure.

Authors:  Kamyar Kalantar-Zadeh; Stefan D Anker; Andrew J S Coats; Tamara B Horwich; Gregg C Fonarow
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

4.  Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.

Authors:  Milton Packer
Journal:  Circ Heart Fail       Date:  2011-09       Impact factor: 8.790

Review 5.  Diabetes and the risk of heart failure.

Authors:  Ravi Dhingra; Ramachandran S Vasan
Journal:  Heart Fail Clin       Date:  2011-10-13       Impact factor: 3.179

6.  Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE).

Authors:  Michel Komajda; Peter E Carson; Scott Hetzel; Robert McKelvie; John McMurray; Agata Ptaszynska; Michael R Zile; David Demets; Barry M Massie
Journal:  Circ Heart Fail       Date:  2010-11-10       Impact factor: 8.790

7.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

Authors:  Michael R MacDonald; Mark C Petrie; Fumi Varyani; Jan Ostergren; Eric L Michelson; James B Young; Scott D Solomon; Christopher B Granger; Karl Swedberg; Salim Yusuf; Marc A Pfeffer; John J V McMurray
Journal:  Eur Heart J       Date:  2008-04-14       Impact factor: 29.983

8.  Role of body size on cardiovascular function: can we see the meat through the fat?

Authors:  Paul D Chantler; Edward G Lakatta
Journal:  Hypertension       Date:  2009-07-06       Impact factor: 10.190

9.  Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.

Authors:  Gülmisal Güder; Stefan Frantz; Johann Bauersachs; Bruno Allolio; Christoph Wanner; Michael T Koller; Georg Ertl; Christiane E Angermann; Stefan Störk
Journal:  Circ Heart Fail       Date:  2009-09-24       Impact factor: 8.790

10.  Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management.

Authors:  Panagiotis Pateinakis; Aikaterini Papagianni
Journal:  Int J Nephrol       Date:  2011-02-06
View more
  65 in total

1.  Sex differences in new-onset heart failure.

Authors:  Sven Meyer; Frank P Brouwers; Adriaan A Voors; Hans L Hillege; Rudolf A de Boer; Ron T Gansevoort; Pim van der Harst; Michiel Rienstra; Isabelle C van Gelder; Dirk J van Veldhuisen; Wiek H van Gilst; Peter van der Meer
Journal:  Clin Res Cardiol       Date:  2014-11-15       Impact factor: 5.460

2.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

3.  Response to Letter Regarding Article, “Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction”.

Authors:  Barry A Borlaug; Horng Chen; Grace Lin; Margaret M Redfield; Gregory D Lewis; Marc J Semigran; Steven E McNulty; Martin LeWinter; Anita Deswal; Kenneth B Margulies
Journal:  Circ Heart Fail       Date:  2015-07       Impact factor: 8.790

4.  Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis.

Authors:  Carolyn L Lekavich; Debra J Barksdale; Jia-Rong Wu; Virginia Neelon; Jamie Crandell; Eric J Velazquez
Journal:  J Card Fail       Date:  2017-07-14       Impact factor: 5.712

Review 5.  Heart failure with preserved ejection fraction: the missing pieces in diagnostic imaging.

Authors:  Sadi Loai; Hai-Ling Margaret Cheng
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 6.  Use of metformin in diseases of aging.

Authors:  John M Miles; Andrew D Rule; Barry A Borlaug
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

Review 7.  Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

Authors:  Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor
Journal:  J Am Coll Cardiol       Date:  2014-11-24       Impact factor: 24.094

8.  Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients.

Authors:  Michael Zacharias; Samuel Joffe; Elizabeth Konadu; Theo Meyer; Michael Kiernan; Darleen Lessard; Robert J Goldberg
Journal:  Int J Cardiol       Date:  2015-10-22       Impact factor: 4.164

9.  Response to Letters Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction".

Authors:  Selma F Mohammed; Margaret M Redfield
Journal:  Circulation       Date:  2015-10-20       Impact factor: 29.690

Review 10.  Pre-clinical diastolic dysfunction.

Authors:  Siu-Hin Wan; Mark W Vogel; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.